TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02509104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC capsule of dutasteride and tamsulosin
Description: Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC capsule of dutasteride and tamsulosin
Description: Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
Description: Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
Description: Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
Study: NCT01840891

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactose H2 breath test (LH2BT)
Description: Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lactose H2 breath test (LH2BT)
Description: Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
Study: NCT01069120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex
Description: 2, 25 mg capsules once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex
Description: 1, 25 mg capsule once per day
Study: NCT00388505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder (TIP) capsules for inhalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Solution for Inhalation
Description: Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
Study: NCT02529267

Intervention type: OTHER
Intervention: Standard of care

Intervention type: OTHER
Intervention: Standard of care
Study: NCT04038840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]UCB-J radiotracer
Description: I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]UCB-J radiotracer
Description: I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-MR
Description: Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-MR
Description: Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
Study: NCT04195373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TMV-018 + 5-FC
Description: TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TMV-018 + anti-PD-1
Description: TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~Anti-PD-1 inhibitor dose according to its SMPC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TMV-018 + 5-FC + anti-PD-1
Description: TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment cycle.~Anti-PD-1 Inhibitor: dose according to its SMPC.
Study: NCT01043419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xenon
Description: Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
Study: NCT01391546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX
Description: 1 dose 0.65 mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ZOSTAVAX
Description: 1 dose 0.65 mL
Study: NCT04012957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desidustat Oral Tablet
Description: Desidustat tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Darbepoetin injection
Study: NCT01213472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
Description: Up to 24 intramuscular administrations
Study: NCT02247765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial line
Description: Arterial line is inserted to draw a CO-Oximeter value as it is the gold standard and as advised in ISO 80601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motion
Description: The subject is asked to move their hand by either rubbing or tapping their fingers at a specified frequency and amplitude during portions of the hypoxic procedure.
Study: NCT02827123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC videolaryngoscopy
Description: Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Macintosh Laryngoscopy
Description: Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
Study: NCT02241291

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. A deflated balloon or other device on a catheter is fed from an artery (such as the inguinal femoral artery or radial artery) up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery
Study: NCT01905124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: CF101 1 mg tablets orally every 12 hours for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets orally every 12 hours for 24 weeks
Study: NCT02709590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium + lidocaine
Description: patients will have of oral diclofenac potassium 60 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will have of oral placebo tablet 60 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
Study: NCT00564005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced therapy (CIT)
Description: restraint of the unaffected arm and practice of the affected arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral arm training (BAT)
Description: bilateral symmetric, repetitive arm training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined therapy (CT)
Description: combined different treatment approaches

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Conventional treatment program
Study: NCT02088814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'EPICAP'
Description: standardized, secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
Study: NCT04644380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVOcell
Description: Female participants undergoing in vitro fertilization (IVF) and or/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproductive will be asked to participate
Study: NCT05804760

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of implant parameters
Description: 1. Examination of the inclusion criteria~2. Medical history/patient-specific data (smoking, tumour diseases, radiation, gender, number of implants, history of periodontitis).~3. Recording of implant-specific parameters (measurement depth at six sites per implant(probing depth/PD), bleeding and or pus on probing (BOP) at six measurement sites per implant, condition of the peri-implant mucosa using the modified plaque index(mPI) and the modified ginigiva index (mGI), measurement of the width of the keratinised mucosa(KM), type of denture, approximal plaque index (API), radiographically detectable bone resorption.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of implant parameters
Description: 1. Examination of the inclusion criteria~2. Medical history/patient-specific data (smoking, tumour diseases, radiation, gender, number of implants, history of periodontitis).~3. Recording of implant-specific parameters (measurement depth at six sites per implant(probing depth/PD), bleeding and or pus on probing (BOP) at six measurement sites per implant, condition of the peri-implant mucosa using the modified plaque index(mPI) and the modified ginigiva index (mGI), measurement of the width of the keratinised mucosa(KM), type of denture, approximal plaque index (API), radiographically detectable bone resorption.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of implant parameters
Description: 1. Examination of the inclusion criteria~2. Medical history/patient-specific data (smoking, tumour diseases, radiation, gender, number of implants, history of periodontitis).~3. Recording of implant-specific parameters (measurement depth at six sites per implant(probing depth/PD), bleeding and or pus on probing (BOP) at six measurement sites per implant, condition of the peri-implant mucosa using the modified plaque index(mPI) and the modified ginigiva index (mGI), measurement of the width of the keratinised mucosa(KM), type of denture, approximal plaque index (API), radiographically detectable bone resorption.
Study: NCT02253368

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sleep

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sleep
Study: NCT01291199

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vardenafil
Description: 10 mg p.o. bid for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vardenafil
Description: 10 mg p.o. bid for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. 6 weeks bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo p.o. 6 weeks bid
Study: NCT01186939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m\^2/day.
Study: NCT01091597

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: usual PV ablation
Description: usual PV ablation, per above

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Box isolation of pulmonary veins
Description: as above
Study: NCT04357704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S0N0
Description: (no ITD)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S0N0
Description: (no ITD)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S0N500
Description: (ITD +500µs on noise)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S0N500
Description: (ITD +500µs on noise)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-500N500
Description: (ITD -500µs on signal and +500 µs on noise)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S-500N500
Description: (ITD -500µs on signal and +500 µs on noise)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S0N1000
Description: (ITD + 1000 µs on noise)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S0N1000
Description: (ITD + 1000 µs on noise)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S0Nuncorr
Description: (no ITD cue, with uncorrelated stimulation frame)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S0Nuncorr
Description: (no ITD cue, with uncorrelated stimulation frame)
Study: NCT01025024

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample
Study: NCT00636688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle - detailed advice
Description: Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - general information
Description: General information about healthy food choices and exercise
Study: NCT03163979

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET/CT and Comet assay guide RapidArc
Description: 1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET/CT and Comet assay guide IMRT
Description: Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RapidArc
Description: RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: 7f-IMRT
Description: seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
Study: NCT01701674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Pre-treatment with ipilimumab (cycle 1): Before the participant's tumor sample is taken to send to the lab for growing the TILs, they will start their first cycle of ipilimumab. This drug is given as an intravenous infusion (through a vein) over a period of about 90 minutes (an hour and a half). Cycle 2 of ipilimumab: About a week after the sample of the participant's tumor was collected for TIL growth (and 3 weeks after their first cycle of ipilimumab), participants will have their second cycle of ipilimumab. This will be another IV infusion, lasting about 90 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Tumor sample for TIL growth in the lab: About 2 weeks after the participant's first cycle of ipilimumab, a sample of their tumor will be collected and sent to the lab for TIL growth. Growing the TILs takes about 6 weeks. If their sample has grown enough TIL cells, participants will continue with the next part of the study. Depending on how long the TILs take to grow in the lab, they may need to repeat some of their laboratory and imaging tests (blood draws, X-rays, and CT or magnetic resonance imaging \[MRI\] scans). TIL Infusion (inpatient): After completing lymphodepletion, participants will be admitted back into the hospital for IV infusion of the TIL cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Lymphodepletion
Description: Lymphodepletion (inpatient hospital stay for about 2 days plus outpatient drug dosing for 5 days): About 4 weeks after their second cycle of ipilimumab, participants will be admitted to the hospital for their first two days of receiving the chemotherapy drug, cyclophosphamide. This drug will be given as an intravenous (IV, meaning through the vein) infusion. After 2 days of receiving cyclophosphamide, if their study doctor thinks that they are well enough, you will be discharged from the hospital and will return for the next 5 days in a row for outpatient IV infusions of the second lymphodepletion chemotherapy, fludarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide as Part of Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine as Part of Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose IL-2
Description: High dose IL-2 (continued inpatient): Participants will remain in the hospital following TIL infusion for receiving high dose IL-2 and recovery. The IL-2 will be given three times per day for about 3-5 days as an IV bolus (meaning through the vein, more quickly than other infusions - in about 15 minutes each dose). Participants will remain in the hospital for approximately 7-14 days until they have recovered from the IL-2 treatments.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive Cell Therapy with TIL
Study: NCT03352102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Neuromuscular electrical stimulation therapy was performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation
Description: Neuromuscular electrical stimulation therapy was performed
Study: NCT00072839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-0600
Description: teduglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo solution injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide 0.05
Description: 0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide 0.2 mg
Description: 0.2 mg/kg/d subcutaneously injected into thigh or abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 dose
Description: 0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide 0.1 mg dose
Description: 0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
Study: NCT02213432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Different timing of influenza vaccination
Description: The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Different timing of influenza vaccination
Description: The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
Study: NCT02136745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Mind-Body Intervention
Description: The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. Three consecutive, mixed-disorder groups, ranging in size from 10 to 18 participants each. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
Study: NCT00395551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5mg intravitreal injection
Study: NCT04248582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: LNSC will be performed with low-pressure liquid nitrogen (\<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor. During each cycle, a surface area of approximately 2 to 3 cm2 is targeted. Up to three sites are treated during each session. Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion. After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes. Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: LNSC will be performed with low-pressure liquid nitrogen (\<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor. During each cycle, a surface area of approximately 2 to 3 cm2 is targeted. Up to three sites are treated during each session. Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion. After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes. Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.